The effective F-1/A enables continuous ATM sales by YA II PN, creating persistent overhang. Monitor daily ADS volume and any Form 4 filings for share resales; expect continued downward pressure on the stock as the selling shareholder monetizes its position. Further downside risk if Nasdaq delisting proceedings advance.
Price Chart
Executive Summary
The SEC declared effective Trinity Biotech's F-1/A registration statement (File No. 333-293717), enabling the resale of up to 33,752,429 ADSs (675,048,580 ordinary shares) by selling shareholder YA II PN, Ltd. under the Standby Equity Purchase Agreement. This activates an ATM program that could further dilute existing shareholders for a micro-cap already under Nasdaq compliance review with negative shareholders' equity.
Key Facts
- SEC effectiveness date: June 10, 2026.
- Registration covers 33,752,429 ADSs (675,048,580 ordinary shares) for resale by YA II PN, Ltd.
- Company has already sold 1,530,537 ADSs under the agreement for aggregate gross proceeds of $859,270.
- Proceeds from resale go to selling shareholder, not the company.
- Company had negative shareholders' equity of -$71.98M and total debt of $124.6M as of FY2025.
- Stock trades at $0.7321 (market cap ~$14M), well below Nasdaq minimum bid price requirement.
Financial Impact
Potential dilution from resale of up to 33.75M ADSs (current market cap ~$14M). Each ADS resold adds supply pressure; at current price, total potential resale value ~$24.7M, representing ~180% of current market cap.
Risk Factors
- Accelerated dilution if YA II PN aggressively sells shares.
- Nasdaq non-compliance and potential delisting.
- Inability to service $124.6M debt; negative equity suggests balance sheet distress.
- Low liquidity could amplify price impact of ATM sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001939 |
| Document: 9999999995-26-001939-index.html | 9999999995-26-001939 |
| Document: 9999999995-26-001939.txt | 9999999995-26-001939 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $5.77 | awaiting T+60 | — | $7.11 (+23.22%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.11 (−11.12%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.11 (−25.94%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.11 (+27.96%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.11 (−32.92%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.11 (−36.35%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.11 (−39.07%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.11 (+1788.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers